Attached files
| file | filename |
|---|---|
| EX-99.1 - EXHIBIT 99.1 - OMNI BIO PHARMACEUTICAL, INC. | d274492dex991.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): December 22, 2011
| Omni Bio Pharmaceutical, Inc. |
(Exact name of registrant as specified in its charter)
| Colorado | 000-52530 | 20-8097969 | ||
| (State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
| 5350 South Roslyn, Suite 430, Greenwood Village, CO 80111 |
(Address of principal executive offices, including zip code)
Registrant’s telephone number, including area code: (303) 867-3415
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 7.01 Regulation FD Disclosure.
On December 22 2011, Omni Bio Pharmaceutical, Inc. (“Omni Bio”) issued a press release announcing that U.S. Patent No. 8,071,551, entitled “METHODS AND COMPOSITIONS FOR TREATING DIABETES (the “Diabetes Patent”), was issued by the United States Patent and Trademark Office on December 6, 2011, and that Omni Bio was licensing the Diabetes Patent under an agreement with Bio Holding, Inc. A copy of the press release is furnished herewith as Exhibit 99.1.
In accordance with General Instruction B.2 of Form 8-K, the information in this Item shall not be deemed “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any filing.
Item 9.01 Financial Statements and Exhibits.
| (d) | Exhibits. |
| 99.1 | Press Release of Omni Bio Pharmaceutical, Inc. dated December 22, 2011 | |
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Omni Bio Pharmaceutical, Inc. | ||||||
| Date: December 22, 2011 | ||||||
| By: | /s/ Robert C. Ogden | |||||
| Robert C. Ogden | ||||||
| Chief Financial Officer | ||||||
3
Exhibit Index
| Exhibit No. |
Description | |
| 99.1 | Press Release of Omni Bio Pharmaceutical, Inc. dated December 22, 2011 | |
4